About Us
Real-time Quotes & News
Market Analysis
Trading Platform
Terms
Promotion
FAQ
Contact
繁
简
EN
繁
简
EN
Promotion
FAQ
Contact
Open Account
Contact Us

Japan's 20-year bond yield rose 4.5 bps to 3.615%.

2026-06-08

Japan's 20-year bond yield rose 4.5 bps to 3.615%.

Other News
2026-06-08

Japan Q1 final nominal GDP +0.6% QoQ (previous +0.8%).

Japan Q1 final nominal GDP +0.6% QoQ (previous +0.8%).
2026-06-08

Individual Stock News 1. Concord New Energy (00182.HK): Total equity power generation in the first five months was 3930.92 GWh. 2. Muyuan Foods (02714.HK): May sales revenue of commercial pigs was approximately RMB 8.565 billion, a year-on-year dec

Individual Stock News 1. Concord New Energy (00182.HK): Total equity power generation in the first five months was 3930.92 GWh. 2. Muyuan Foods (02714.HK): May sales revenue of commercial pigs was approximately RMB 8.565 billion, a year-on-year decrease of 30.13%. 3. Truly International (00732.HK): May net operating revenue was approximately HKD 1.217 billion, a year-on-year decrease of approximately 13.4%. 4. Powerlong Real Estate (01238.HK): Total contracted sales in the first five months were approximately RMB 2.79 billion, a year-on-year decrease of 11.93%. 5. Zhongliang Holdings (02772.HK): Cumulative contracted sales in the first five months were approximately RMB 3.12 billion, a year-on-year decrease of 41.9%. 6. Longyuan Power (00916.HK): Cumulative power generation in the first five months was 33.434 million MWh, a year-on-year decrease of 1.29%. 7. Zhenro Properties (06158.HK): Contracted sales for the first five months totaled approximately RMB 1.726 billion, a decrease of 12.07% year-on-year. 8. China Investment & Financing (01226.HK) issued a profit warning: Annual net profit is expected to be between HKD 125 million and HKD 150 million, turning around from a loss to a profit year-on-year. 9. Zhipu (02513.HK) and MINIMAX-W (00100.HK) will be officially included in the Hang Seng TECH Index starting June 8th, with initial weights of 0.53% and 0.36% respectively. 10. Henlius Biotech (02696.HK): The first US patient has been dosed in an international multicenter Phase 1 clinical trial of its pembrolizumab biosimilar HLX17 in patients with various resected solid tumors.
Open Account
Demo Account
Contact Us
About Us Real-time Quotes & News Market Analysis
 Trading Platform Market Analysis Promotion Terms Promotion FAQ Contact
Copyright © 2026 Aspire Global Company Limited. All Rights Reserved.
Terms of Use and Privacy
Disclaimer

Disclaimer: ASPIRE is not responsible for the content of any analysis, advice, comment, suggestion, research report or market data in this website and links to third-party websites or resources. All the information mentioned above only represents the view of corresponding author. ASPIRE cannot and does not warrant the accuracy, validity, timeliness or completeness of any such information. You should conduct individual assessments and other proper research to make their investment decisions. The materials and information contained in this website are provided for reference only and do not constitute or form an offer, invitation, solicitation or investment advice or recommendation to acquire or dispose of any investment products or services. The price of any financial instruments described in this website may fall as well as rise. Past performance should not be taken as an indication of future performance. The risk disclosure statements do not purport to disclose or discuss all of the risks and other significant aspects of any financial instruments mentioned in this website. You should make your own appraisal of the risk and should consult to the extent necessary your own legal, tax, financial or other professional advisers in respect of any financial instruments mentioned in this website prior to entering into any transaction.

Risk Warning: Leveraged Precious Metals trading on margin carries significant risks and is not suitable for all investors. Please be sure to make investments within your own tolerance after fully understand the risks involved.

Registered & Business Address: Room 1905-1906, 19/F, Eastern Commercial Centre, 395-399 Hennessy Road, Hong Kong

Aspire Global Company Limited is not available to provide services for the residents of certain jurisdictions such as Afghanistan, the United States of America, the Islamic Republic of Iran, North Korean.